Ovarian Hyperstimulation Syndrome, Pregnancy
Conditions
Keywords
dual trigger, hCG, GnRH agonist, ICSI, pregnancy, OHSS
Brief summary
The use of antagonist controlled ovarian stimulation protocols has allowed the use of GnRH agonist to be used for final oocyte maturation. The use of GnRH agonist as ovulation trigger has been shown to reduce the risks for ovarian hyperstimulation syndrome (OHSS), but its sole use results in reduced embryo implantation due to luteal phase insufficiency. The combination of GnRH agonist and variable doses of hCG for final oocyte maturation has been shown to overcome the luteal phase insufficiency effecting endometrial receptivity. In this study the investigators will test the hypothesis that using GnRH agonist (0.2mg Triptorelin) and a full dose of hCG (6500IU Ovitrelle) for final oocyte maturation in normoresponders will increase oocyte maturity, embryo quality and embryo implantation and reduce ovarian hyperstimulation syndrome, as compared to the traditional hCG (full dose) alone trigger.
Interventions
PROCEDUREfinal oocyte maturation trigger
when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
Sponsors
Antalya IVF
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Age; \< 40 years * Cycle number; cycles 1 or 2 * Antral follicle count; \>10 and \<25 * BMI; \>18 and \<30 * Normogonadotrophic cycle length; 24 to 25 days * Male; ejaculated semen only
Exclusion criteria
* Presence of endocrine disorders; (diabetes mellitus, hyperprolactinemia, thyroid dysfunction, congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome) * Previous major uterine surgery (that would affect endometrial receptivity) Secondary
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| embryo implantation rate | 12 months | the number of fetal sacs per embryo transferred to a patient's uterus |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| oocyte maturation | 12 months | the percentage of oocytes that are at the metaphase II (nuclear mature) stage at the time of oocyte collection |
| Ovarian hyperstimulation syndrome | 12 months | a complication arising from ovarian hyperstimulation with the use of exogenous hormones and ovulation induction |
Other
| Measure | Time frame | Description |
|---|---|---|
| clinical pregnancy | 12 months | the number of patients with an ultrasound confirmed fetal heart 7 weeks after the transfer of embryos to patient uteruses |
Countries
Turkey (Türkiye)
Outcome results
None listed